As shown in Fig. 2b, miR-9 was differentially expressed in the breast cancer molecular subgroups (p < 0.001 Kruskall-Wallis test), with the highest expression levels in the basal like and HER2 enriched PAM50 subtypes, and the lowest in the two luminal subtypes. This evidence concerns the gene ERBB2 and breast carcinoma.